Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is indicated as adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Initial:** 5 mg twice daily.
* **Titration:** Increase dose as needed, not more often than weekly, based on clinical response and tolerability.
* **Maintenance:** Typically 10 mg twice daily (20 mg/day).
* **Maximum:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2 to <10 years or weighing <30 kg)
* **Initial:** 2.5 mg twice daily.
* **Titration:** Increase dose as needed, not more often than weekly, based on clinical response and tolerability.
* **Maintenance:** Typically 5 mg twice daily (10 mg/day).
* **Maximum:** 10 mg twice daily (20 mg/day).
*Note: Dosing for pediatric patients ≥10 years or weighing ≥30 kg can follow adult dosing recommendations.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosage adjustments are recommended, but initiation at the lower end of the dosing range and slow titration is advised.
* **Renal Impairment:** No specific dosage adjustments are recommended, but use with caution.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence (most common), lethargy, drooling, constipation, decreased appetite, respiratory infections, ataxia, vomiting, irritability, aggression.
* **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms upon abrupt discontinuation, paradoxical reactions (e.g., excitation, aggression).
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and profound CNS depression.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease clobazam plasma concentrations.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin):** May increase clobazam plasma concentrations.
* **CYP2C19 Substrates (e.g., clopidogrel, proton pump inhibitors):** Clobazam is a moderate inhibitor of CYP2C19; monitor for increased effects of these substrates.
## Monitoring
* **Seizure frequency and type:** Assess for efficacy.
* **Signs of CNS depression:** Monitor for somnolence, ataxia, and cognitive impairment.
* **Behavioral changes:** Monitor for agitation, aggression, and suicidal ideation.
* **Signs of withdrawal:** Monitor during dose reduction or discontinuation.
* **Suicidal behavior and ideation:** Patients treated with antiepileptic drugs (AEDs) for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
## Clinical Pearls
* Clobazam is intended for adjunctive use only in LGS.
* Gradual titration and slow tapering are crucial to minimize withdrawal symptoms.
* Consider the risk of serious skin reactions, especially with concurrent use of other drugs known to cause them.
* Patients should be advised not to drive or operate heavy machinery until they know how clobazam affects them.
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details before making any therapeutic decisions.
